{
    "clinical_study": {
        "@rank": "63761", 
        "arm_group": {
            "arm_group_label": "Flexofytol (bio-optimized curcumin)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of bio-optimized curcumin(Flexofytol)\n      during a 90-days period in knee ostearthritis patients on the serum levels of specific\n      biomarkers of osteoarthritis and on the evaluation of pain."
        }, 
        "brief_title": "Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  45 to 80 years of age\n\n          -  Internal femorotibial gonarthrosis responding to the clinical and radiological\n             criteria of ACR\n\n          -  Symptomatic knee for more than 6 months\n\n          -  Mean knee pain on the last 24 hours of at least 40 mm on VAS\n\n          -  Kellgren & Laurence grade II to III\n\n          -  Patients able to avoid NSAIDs and analgesics during the study\n\n          -  Patients having signed informed consent\n\n          -  Patients able to follow the study instructions\n\n        Exclusion Criteria:\n\n          -  Related to the osteoarthritis pathology:\n\n               -  Osteoarthritis linked to a metabolic arthropathy\n\n               -  Predominant associated symptomatic femoropatellar osteoarthritis\n\n               -  Chondromatosis or villonodular synovitis of the knee\n\n               -  Recent trauma (< 1 month) of the knee responsible for the pain\n\n               -  Inflammatory flare\n\n               -  Pathology potentially interfering with the evaluation (metabolic inflammatory\n                  arthropathy, rheumatoid arthritis, lower limb radiculalgia, arthritis...\n\n               -  Paget disease\n\n               -  Homolateral coxarthrosis\n\n               -  Articular Prosthesis\n\n               -  Knee joint effusion\n\n          -  Related to previous and associated treatments:\n\n               -  Corticosteroids injection in the previous month, whatever the joint concerned,\n\n               -  Hyaluronan injection in the evaluated knee during the previous 6 months,\n\n               -  NSAID or analgesics in the 72 hours prior to inclusion\n\n               -  No modification of Slow-acting drugs for OA and/or dietary supplements taken\n                  within less than 6 months prior to the study(ex: chondroitin sulfate, diacerein,\n                  soy and avocado unsaponifiables, oxaceprol, granions de cuivre, glucosamine,\n                  phytotherapy for OA, homeopathy for OA...),\n\n               -  Anticoagulant (coumarinic) treatment and heparin\n\n               -  General corticotherapy,\n\n               -  Contraindication to paracetamol.\n\n          -  Related to associated pathologies:\n\n               -  Patient suffering from serious associated illness (liver failure, kidney\n                  failure, non-controlled cardiovascular diseases...)\n\n          -  Related to patients:\n\n               -  Pregnant or breastfeeding women\n\n               -  Pre-menopausal women with no contraception\n\n               -  Patients unable to write\n\n               -  Patients enrolled in a clinical trial in the previous 3 months\n\n               -  Patients under juristic protection or under guardianship."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01909037", 
            "org_study_id": "TILFLEXFY 002"
        }, 
        "intervention": {
            "arm_group_label": "Flexofytol (bio-optimized curcumin)", 
            "description": "2x3 caps/day (before breakfast and in the evening) for 3 months", 
            "intervention_name": "Flexofytol (bio-optimized curcumin)", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": "Curcumin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "osteoarthritis", 
            "curcumin", 
            "biomarker", 
            "pain"
        ], 
        "lastchanged_date": "July 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Liege", 
                    "country": "Belgium", 
                    "zip": "4000"
                }, 
                "name": "Citadelle Hospital"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis", 
        "overall_official": [
            {
                "affiliation": "Citadelle Hospital of Liege", 
                "last_name": "Caroline Castermans, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Tilman S.A.", 
                "last_name": "Yvan Dierckxsens", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Belgium: Ethics Committee", 
                "Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment"
            ]
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change from baseline of serum levels of biomarkers", 
            "measure": "Serum levels of biomarkers of cartilage metabolism and inflammation", 
            "safety_issue": "No", 
            "time_frame": "84 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01909037"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change from baseline of the mean pain over the last 24 hours and of the global assessment of disease activity by the patient", 
            "measure": "Pain and the global patient assessment of disease activity using a Visual Analog Scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "84 days"
        }, 
        "source": "Tilman S.A.", 
        "sponsors": {
            "collaborator": {
                "agency": "Bioxtract SA", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Tilman S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}